WHWK Whitehawk Therapeutics Inc.
- Stocks
- Healthcare
- NASDAQ: WHWK
Price (delayed)
$2.1
Market cap
$98.97M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.06
Enterprise value
-$45.97M
Relative Growth:
Rel. Growth:
31
Relative Strength:
Rel. Strength:
67
Relative Valuation:
Rel. Valuation:
10
Relative Profitability:
Rel. Profitability:
42
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is
Highlights
The debt has plunged by 100% YoY
WHWK's quick ratio is up by 7% since the previous quarter
The company's EPS has shrunk by 138% QoQ but it has surged by 98% YoY
The company's net income has shrunk by 138% QoQ but it has surged by 84% YoY
Whitehawk Therapeutics's revenue has decreased by 22% from the previous quarter and by 9% YoY
The company's gross profit fell by 22% QoQ and by 7% YoY
Key stats
What are the main financial stats of WHWK
Market
Valuations
Earnings
Shares outstanding
47.13M
Market cap
$98.97M
Enterprise value
-$45.97M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.57
Price to sales (P/S)
6.72
PEG
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-2.13
Revenue
$21.6M
Gross profit
$19.24M
Operating income
-$102.33M
Net income
-$10.42M
EBIT
-$10.38M
EBITDA
-$9.91M
Free cash flow
-$96.49M
Per share
Balance sheet
Liquidity
EPS
-$0.06
EPS diluted
-$0.07
Free cash flow per share
-$1.4
Book value per share
$3.65
Revenue per share
$0.31
TBVPS
$2.62
Total assets
$180.82M
Total liabilities
$8.76M
Debt
$0
Equity
$172.07M
Working capital
$169.92M
Debt to equity
0
Current ratio
20.41
Quick ratio
20.24
Net debt/EBITDA
14.63
Margins
Efficiency
Dividend
EBITDA margin
-45.9%
Gross margin
89.1%
Net margin
-48.2%
Operating margin
-473.8%
Return on assets
-7.3%
Return on equity
-8.1%
Return on invested capital
-47.7%
Return on capital employed
-6%
Return on sales
-48.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
WHWK stock price
How has the Whitehawk Therapeutics stock price performed over time
Intraday
-6.67%
1 week
-6.67%
1 month
-2.33%
1 year
-0.94%
YTD
-33.44%
QTD
10.53%
Financial performance
How have Whitehawk Therapeutics's revenue and profit performed over time
Revenue
$21.6M
Gross profit
$19.24M
Operating income
-$102.33M
Net income
-$10.42M
Gross margin
89.1%
Net margin
-48.2%
The net margin has plunged by 148% from the previous quarter but it has soared by 82% YoY
The company's net income has shrunk by 138% QoQ but it has surged by 84% YoY
The operating margin has shrunk by 108% QoQ and by 60% YoY
The operating income has dropped by 62% since the previous quarter and by 45% year-on-year
Price vs fundamentals
How does WHWK's price correlate with its fundamentals
Growth
What is Whitehawk Therapeutics's growth rate over time
Valuation
What is Whitehawk Therapeutics stock price valuation
P/E
N/A
P/B
0.57
P/S
6.72
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-2.13
The company's EPS has shrunk by 138% QoQ but it has surged by 98% YoY
The company's equity has surged by 118% YoY but it fell by 22% QoQ
WHWK's price to book (P/B) is 59% less than its 5-year quarterly average of 1.4 and 29% less than its last 4 quarters average of 0.8
The price to sales (P/S) is 92% more than the last 4 quarters average of 3.5 but 72% less than the 5-year quarterly average of 24.1
Whitehawk Therapeutics's revenue has decreased by 22% from the previous quarter and by 9% YoY
Efficiency
How efficient is Whitehawk Therapeutics business performance
The company's return on sales has shrunk by 148% QoQ but it has surged by 82% YoY
The return on invested capital has dropped by 143% since the previous quarter but it has surged by 68% year-on-year
The return on assets has dropped by 132% since the previous quarter but it has surged by 86% year-on-year
The company's return on equity has shrunk by 131% QoQ but it has surged by 88% YoY
Dividends
What is WHWK's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for WHWK.
Financial health
How did Whitehawk Therapeutics financials performed over time
Whitehawk Therapeutics's total assets has surged by 78% YoY but it has decreased by 23% QoQ
The total liabilities has shrunk by 62% YoY and by 29% QoQ
The debt is 100% less than the equity
The company's equity has surged by 118% YoY but it fell by 22% QoQ
The debt has plunged by 100% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.